THOMPSON, Amy N.; RAGUCCI, Kelly R.; FERMO, Joli D.; WHITLEY, Heather P.
Evaluation of patient perceptions and outcomes related to anticoagulation point-of-care testing in ambulatory care clinics
Centro de investigaciones y Publicaciones Farmacéuticas
Granada, España

Available in: http://www.redalyc.org/articulo.oa?id=69015283004
ABSTRACT

Until recently, Prothrombin Time/International Normalized Ratio (PT/INR) measurements have typically been used to monitor patients on warfarin through institutional laboratories via venous puncture. The Point-of-Care Testing (POCT) device has revolutionized the patient care process by allowing for laboratory testing outside of the central laboratory.

Objective: To analyze humanistic and clinical outcomes in patients currently treated with warfarin and monitored through a pharmacist-managed anticoagulation clinic using point-of-care testing (POCT) device versus venipuncture within ambulatory care clinics at our institution.

Methods: All patients currently treated with warfarin therapy who were managed by clinical pharmacists for anticoagulation monitoring at the Medical University of South Carolina (MUSC) Family Medicine Center and University Diagnostic Center, were enrolled. Patients were asked to complete a satisfaction survey regarding their anticoagulation monitoring. In addition, data related to emergency department (ED) visits, hospitalizations and percent of time in the INR therapeutic range for 6 months pre- and post-implementation of POCT device was collected. This information was obtained through an electronic patient information database, Oacis.

Results: A total of 145 patients were included in the data collection from the two clinics. The majority (41%) of these patients were taking warfarin for atrial fibrillation. Satisfaction surveys were completed by 86 (59%) of patients. The surveys revealed that POCT device was preferred over venipuncture in 95% of patients. Reasons for the preference included more face-to-face interaction, less wait time, less pain, less blood needed, and quicker results. Of the 145 patients who were included in the objective data analysis, no significant differences were found in the number of hospitalizations, ED visits, or percent of time in the INR therapeutic range pre- and post-implementation of POCT device.

Conclusion: The results of this study demonstrate improvement in patient satisfaction with POCT compared to venipuncture, with limited value in clinical outcomes.

Keywords: Point-of-Care Systems. Patient Satisfaction. Pharmaceutical Services. United States.
INTRODUCTION

Due to its narrow therapeutic index, risk of life-threatening adverse effects, and numerous drug-drug, drug-food, and drug-disease interactions, warfarin therapy requires close and careful monitoring. Prothrombin Time/International Normalized Ratio (PT/INR) measurements have traditionally been monitored through institutional laboratories via venipuncture. Point-of-Care Testing (POCT) devices have revolutionized the patient care process by allowing for laboratory testing outside of the central laboratory. The portability of the POCT device has facilitated INR testing that may be performed in various settings including nursing homes, at the patient’s bedside, and in ambulatory care clinics. Although various recent studies have addressed the accuracy of these devices compared to traditional laboratory testing, there has been no published data available evaluating both humanistic and clinical outcomes in pharmacist-managed clinics. At the Medical University of South Carolina (MUSC), there are three pharmacist-managed anticoagulation clinics where POCT device is utilized. Prior to the implementation of the POCT device in these clinics, warfarin management was an extremely time consuming process for both the patient and the practitioner. Patients would go to the laboratory for venipuncture and the practitioner would await the results, review the patient chart/current regimen, contact the patient via telephone with the results and finally make necessary adjustments. The turnaround time from venipuncture to receiving results was 5 hours on average. Point-of-care testing, on the other hand, altered our practice model in such a way that telephone contacts became unnecessary and the process became more streamlined. Patients arrive for their appointment with the clinical pharmacist and receive point-of-care testing followed by education and management of warfarin at the time of the visit. Follow-up appointments are made as well (2 weeks if results are not in range; 4 weeks if results are in range) and the patients are given reminder cards with new dosing instructions attached. It should be noted that the average time spent in clinic is 20-30 minutes for patients, regardless of the method utilized. The purpose of this project was to analyze humanistic and clinical outcomes in patients currently treated with warfarin and monitored through a pharmacist-managed anticoagulation clinic using the POCT device at our institution.

METHODS

All patients treated with warfarin therapy and managed by clinical pharmacists for anticoagulation monitoring at the MUSC Family Medicine Center (FMC), and at the MUSC University Diagnostic Center (UDC) were enrolled in the study. The study was conducted for one year post-implementation of the POCT device and approved by the Institutional Review Board (IRB) at MUSC. It should be noted that these two clinics were similar with regard to patient populations and type of services provided. Patients ≤ 18 years of age and patients who refused care with the POCT system were excluded from data collection. The number of hospitalizations and ED visits and the percent of time in the INR therapeutic range for 6 months pre- and post-implementation of the POCT device, was collected on each patient through a retrospective chart review. Percent of time in the INR therapeutic range was determined by taking the total number of INRs in range during the 6 month time period and divided by the total number of INRs obtained during that time period. It should be noted that only those ED visits and hospitalizations related to a major/minor bleed or thromboembolism were recorded. Major bleeds were defined as those considered life-threatening (intracranial or retroperitoneal) or those requiring a blood transfusion. Minor bleeds were those reported but not requiring additional testing or intervention. Data was collected via an electronic patient information database, Oacis. Currently installed in over 100 health care delivery facilities in the United States, Canada and Australia, it is the primary source for our laboratory data as well as inpatient medications, microbiology, pathology and radiology data. Oacis enables the user to create a comprehensive and unified patient record from multiple sources such as ancillary systems or other electronic medical records, and bridge the gap between inpatient and outpatient systems. A two-tailed Fisher’s exact test was utilized to determine statistical significance of hospital admissions, ED visits and percent of time within INR range prior and post POCT implementation. Each patient was also asked to complete a survey to assess patient satisfaction with the POCT device during an on-site visit. This survey was given to patients once they had at least two consecutive months of POCT.
RESULTS

All 180 clinic patients were evaluated for our study, of which 145 were included in the final data analysis evaluating objective data. Thirty five patients refused to try POCT from the beginning and could not be included. Satisfaction surveys were completed by 86 (59%) of the patients.

The majority of patients were female (65%) and the average age at enrollment was 65 (range 23-92). Approximately 50% of patients enrolled were Caucasian and 50% African American (Table 1). The mean time patients were on warfarin therapy was 59 months (range 6-276 months) and 92% of patients were currently stabilized on the medication (two consecutive months within therapeutic range). Of the 86 patients completing patient satisfaction survey, 82 (95%) preferred the POCT device to venipuncture. One patient (1%) patient preferred venipuncture, stating that pain from the finger prick was more uncomfortable than venipuncture, and 3 (4%) did not respond to this question. When looking at indications for warfarin reported from the patient satisfaction surveys and verified within Oacis, 36 (41%) of the patients, were using warfarin therapy for atrial fibrillation. Other indications included deep venous thrombosis (21%), pulmonary embolism (12%), valve replacement (7%) and other (14%). These other indications included antiphospholipid antibody, cancer, pulmonary hypertension, and protein C and S deficiency. A total of 4 (5%) patients did not know their indication for warfarin therapy on the survey.

Table 1. Patient Demographics

<table>
<thead>
<tr>
<th>Gender: number (%)</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>51 (35%)</td>
<td>94 (65%)</td>
</tr>
</tbody>
</table>

<p>| Age (in years): Average (range, SD) | 65 (23-92, 15) |</p>
<table>
<thead>
<tr>
<th>Race: Number (%)</th>
<th>Caucasian</th>
<th>African American</th>
<th>Hispanic</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>72 (49.7%)</td>
<td>72 (49.7%)</td>
<td>1 (0.6%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Therapeutic INR Range</th>
<th>1.5-2.0</th>
<th>2.0-3.0</th>
<th>2.5-3.5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 (1.3%)</td>
<td>118 (81.3%)</td>
<td>25 (17.4%)</td>
</tr>
</tbody>
</table>

Of the patients who preferred the POCT device to venipuncture, the fact that results were obtained more quickly was most important to our patients, with a mean likert score of 4.5 (1 – least important; 5 – most important). Other common reasons for preferring the POCT device over venipuncture included less wait time, less pain, written dosing schedule provided, less blood needed and face-to-face interaction with the practitioner (Figure 1). A total of 76 (88%) patients surveyed stated they would recommend the POCT device to others for PT/INR monitoring. Patients reporting that they would not recommend the POCT device to others gave no explanation for this selection.
Although the study was not designed to evaluate gender or ethnic differences with regard to survey results, none were seen. There was no significant difference seen in other objective data collected including hospitalizations (p=0.618), ED visits (p=0.722), and percentage of time within the INR therapeutic range (p=0.887) pre- and post-implementation of the POCT device in our clinics (Table 2). It should be noted that adherence to appointments did not differ pre- and post-implementation of POCT.

DISCUSSION

Limited published data exist regarding humanistic outcomes with anticoagulation POCT in pharmacist run anticoagulation clinics.\(^1,2\)

Yamreudeewong and colleagues conducted a study with 32 patients, the primary objective was to evaluate the accuracy of the POCT device, Co mumtrak, and to demonstrate the effects of pharmacist intervention on managing patients receiving warfarin therapy.\(^1\) Patients were asked to complete a questionnaire about their preference of monitoring method. The questionnaire focused on convenience, pain/discomfort, and the patient’s feeling about the accuracy of the POCT device. Of the patients surveyed, 25 (78%) reported that they preferred the POCT device over venipuncture. Chapman and colleagues conducted a similar study, 45 patients, evaluating the accuracy, clinical correlation, ease of use, and patient acceptance of two separate POCT devices, CoaguChek and the ProTime Microcoagulation System.\(^2\) As with our study, the majority of patients surveyed, 35 (77.8%), preferred the POCT device to venipuncture. Similar reasons for preferring the POCT device over venipuncture were stated in Chapman’s study; less pain, less difficulty obtaining blood, less anticipated time needed for clinic visit. Forty-one patients (91%) stated they would recommend the POCT device to others. A study performed by Gardiner and colleagues conducted a prospective study to evaluate the accuracy of the POCT device in pharmacist-run clinics. The great majority (95%) of patients indeed prefer POCT to traditional venipuncture rather than simply percent of time in INR therapeutic range. Although we had fewer patients respond to the survey than originally anticipated, our numbers are larger than the other limited published data evaluating humanistic outcomes or percent of time in INR therapeutic range.

While larger than most of the currently published literature, a future study evaluating all the patients followed in our pharmacist run clinics would supply much larger numbers. A potential limitation included the use of a non-validated survey, with a potential bias toward POCT testing with the Likert scales. We feel that our study is unique in the fact that it evaluates both humanistic and objective outcomes for patients utilizing POCT compared to traditional venipuncture. In fact, we decided specifically to evaluate patient oriented evidence such as ED visits and hospitalizations, rather than simply percent of time in INR therapeutic range. Although we had fewer patients respond to the survey than originally anticipated, our numbers are larger than the other limited published data evaluating humanistic outcomes or percent of time in INR therapeutic range.

CONCLUSIONS

Prior to this study, the use of the POCT device had not previously been studied in our clinics, and there is limited published data available evaluating both humanistic and clinical outcomes with the POCT device in pharmacist-run clinics. The great majority (95%) of patients prefer POCT to venipuncture for INR monitoring at our institution. No significant difference was found between POCT and venipuncture with regard to hospitalizations, ED visits or percentage of time within the INR therapeutic range.

CONFLICT OF INTEREST

None of the above mentioned authors have any conflict of interest to disclose with regards to this research project.

References


Welcome to the 16th ISPW!
Welcome to Lisboa!

16 COMMUNICATION AND INFORMATION IN PHARMACY
LISBON, 23rd / 26th AUGUST 2010
Faculdade de Farmacia da Universidade de Lisboa
Communication and information in pharmacy

This is a preliminary short announcement for the 16th ISPW

Host Institution and Venue
Faculty of Pharmacy, University of Lisbon, Portugal

Dates
23rd to 26th August 2010

Key note Speakers and further information soon to be announced at
www.ff.ul.pt/16ISPW

For any inquiries, please use the following email address: 16ISPW@ff.ul.pt

Hope to see you here in Summer 2010!

www.pharmacypractice.org (ISSN: 1886-3655)
Stockley’s Herbal Medicines Interactions available from Pharmaceutical Press

Stockley’s Herbal Medicines Interactions edited by Elizabeth Williamson, Samuel Driver and Karen Baxter, is a new major reference work from Pharmaceutical Press, publishers of core pharmaceutical titles such as Stockley’s Drug Interactions, Martindale and the BNF.

The resource, published earlier this year, is the first professional-level major reference work to bring together available clinical and experimental interactions data on over 150 of the most commonly used herbal medicines, dietary supplements and nutraceuticals in highly structured, fully referenced and rigorously assessed monographs.

It is a uniquely authoritative collaboration between practising clinical pharmacists and experts in the fields of drug interactions, clinical herbal medicines, phytopharmacovigilance and regulation of herbal medicinal products.

Professor Michael Heinrich, University of London, UK, has said “Pharmacists, clinicians and other healthcare providers as well as practitioners of alternative medicines will welcome the addition to the respected Stockley family of this considered, pragmatic approach to herbal medicines interactions.”

Stockley’s Herbal Medicines Interactions can be purchased in print or on CD-ROM at www.pharmpress.com. It is available online at www.medicinescomplete.com.

ENDS

For further information, please contact
Lisa Oliver, Senior Marketing Executive
Pharmaceutical Press
(0)20 7572 2346
lisa.oliver@rpsgb.org

If you would like to discuss bulk sale discounts please contact charlotte.mason@rpsgb.org